Ryoichi Miura

Hiroshima, 7348553, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications

A Study on the Association Between Treatment Response to Atezolizumab Plus Bevacizumab Combination Therapy for Advanced Hepatocellular Carcinoma and Gut Microbiota.

A Study on the Association Between Treatment Response to Atezolizumab Plus Bevacizumab Combination Therapy for Advanced Hepatocellular Carcinoma and Gut Microbiota.

Journal: Microorganisms
Published: March 08, 2026

Reply to "IL-6 as a biomarker in atezolizumab plus bevacizumab in patients with hepatocellular carcinoma".

Reply to "IL-6 as a biomarker in atezolizumab plus bevacizumab in patients with hepatocellular carcinoma".

Journal: Journal of gastroenterology
Published: February 26, 2026

Spatial profiling of chronic liver disease: a pilot spatial case series.

Spatial profiling of chronic liver disease: a pilot spatial case series.

Journal: Scientific reports
Published: December 03, 2025

Efficacy and Safety of Second-Line Lenvatinib After First-Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma.

Efficacy and Safety of Second-Line Lenvatinib After First-Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: October 18, 2025

The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular Carcinoma.

The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular Carcinoma.

Journal: Internal medicine (Tokyo, Japan)
Published: September 03, 2025

Normal adrenocorticotropic hormone levels do not exclude adrenal insufficiency during immune checkpoint inhibitor therapy: evidence from clinical, steroid, and structural analyses.

Normal adrenocorticotropic hormone levels do not exclude adrenal insufficiency during immune checkpoint inhibitor therapy: evidence from clinical, steroid, and structural analyses.

Journal: Frontiers in endocrinology
Published: August 11, 2025

Analysis of the treatment outcome of duodenal varices: A retrospective case series of 15 patients from a single institution.

Analysis of the treatment outcome of duodenal varices: A retrospective case series of 15 patients from a single institution.

Journal: DEN open
Published: March 05, 2025

Multiomics Analysis of Liver Molecular Dysregulation Leading to Nonviral-Related Hepatocellular Carcinoma Development.

Multiomics Analysis of Liver Molecular Dysregulation Leading to Nonviral-Related Hepatocellular Carcinoma Development.

Journal: Journal of proteome research
Published: February 21, 2025

Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization (Sandwich Strategy) versus Atezolizumab plus Bevacizumab Alone in Hepatocellular Carcinoma: A Multicenter Retrospective Study.

Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization (Sandwich Strategy) versus Atezolizumab plus Bevacizumab Alone in Hepatocellular Carcinoma: A Multicenter Retrospective Study.

Journal: Liver cancer
Published: February 19, 2025

Noninvasive prediction of the clinical benefit of immunotherapy in hepatocellular carcinoma.

Noninvasive prediction of the clinical benefit of immunotherapy in hepatocellular carcinoma.

Journal: Journal of gastroenterology
Published: January 29, 2025

Prediction of Hepatocellular Carcinoma After Hepatitis C Virus Sustained Virologic Response Using a Random Survival Forest Model.

Prediction of Hepatocellular Carcinoma After Hepatitis C Virus Sustained Virologic Response Using a Random Survival Forest Model.

Journal: JCO clinical cancer informatics
Published: December 18, 2024

Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma.

Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma.

Journal: Medicine
Published: September 17, 2024
Showing 1-12 of 35

Last Updated: 09/26/2026